1 / 25

Discussion Antonio Frassoldati Oncologia Clinica

This house believes that neoadjuvant systemic therapy should be the standard of care for HER2+/triple negative operable breast cancer > 2cm. Discussion Antonio Frassoldati Oncologia Clinica Az Ospedaliero Universitaria di Ferrara. When a therapy becomes standard?.

lilliand
Download Presentation

Discussion Antonio Frassoldati Oncologia Clinica

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. This house believes that neoadjuvant systemic therapy should be the standard of care for HER2+/triple negative operable breast cancer > 2cm Discussion Antonio Frassoldati Oncologia Clinica Az Ospedaliero Universitaria di Ferrara

  2. When a therapy becomes standard? • Class I evidence of improvement in OS in respect with the previous standard • If not for OS, evidence of improvement in DFS • If not for OS and DFS, evidence of improvements in QoL, side effect profile or costs.

  3. Neoadjuvant vs adjuvant Mauri, JNCI 2005

  4. What is the benchmark?Results of adjuvant therapies Might NAST strategy improve this figure through a personalized approach? HER2+: B31/N9831, JCO 2011; TN : E1199, SABCS 2014, BCCA group

  5. Challenge of demonstrating improved EFS with neoadjuvant therapy Presented By Angela DeMichele at 2015 ASCO Annual Meeting

  6. Increased pCR rate with multiple antiHER2 agents Multiple block with chemotherapy plus T+L, or T+P, versus single block

  7. Increased pCR rate with Carboplatin or Bevacizumab in TNBC Chen, PlosOne 2014

  8. Prognostic Predictive The possibility to increase pCR does justify the neoadjuvant use? Presented By Angela DeMichele at 2015 ASCO Annual Meeting

  9. Trial-level correlation between treatment effect on pCR and outcome Little association between increase in frequency of pathological complete response and treatment’s effect on EFS or OS Cortazar, Lancet 2014

  10. Why NAST results do not translate in long-term results? • In most trials, heterogeneous tumour subtypes were enrolled: possible effect due to different response in different subtypes. • A targeted therapy was used in only three trials (GeparQuattro, NOAH and TECHNO) (and adjuvant trastuzumab used only in NOAH): the degree of difference in pCR is important for long term outcome. • Postoperative therapy could have partly contributed to the treatment effect. • Factors unrelated to primary tumour response could have had a role.

  11. NAST in more homogeneous tumorsPatient-level Meta-Analysis azard Ratios for pCR vs No pCR in HER2+ BC Broglio, Jama Oncol 2016

  12. Trial-level Treatment Benefit for pCR vs Corresponding EFS-HR Between Treatment Arms for Randomized Trials in HER2 BC Modest correlation with pCR odds ratio and EFS HR, but not with OS HR Broglio, Jama Oncol 2016

  13. Why NAST should be the standard? Increase in the rate of breast conservation Improvement in axillary surgery (avoiding axillary clearence in cN1 pts) Increase in the disease outcome (DFS, DDFS, OS)? Increase the kwnoledge of the disease behavior (prognostic; useful for adjuvant phase) Increase in the possibility of tailoring therapies (to increase the pCR or the long term outcomes)

  14. Response and survival to NAST of intrinsic subtypes n-pCR pCR Prat, BMCmed 2015

  15. How precise we are in selection of the optimal candidate to NAST? Caray , ASCO 2013

  16. PIK3CA mutation is associated with lower activity of anti-HER2 agents Loibl, Ann Oncol 2016

  17. TN subtypes are associated with different probability of pCR with NAST Lehmann, PlosOne 2016

  18. Odds ratio of pCR vs n-pCR by type of TN subtype classifier Lehmann, PlosOne 2016

  19. pCR rate according to disease subtypes and TILs Carbognin, The Oncologist 2016

  20. NAST: already standard or still a model for reasearch? • Are the endpoints of therapy the same if therapy is given before or after surgery? • Some of them can be influenced by the timing of therapy • The tumor biology may not be the same for primary or micrometastatic tumor cells

  21. Tumor dormancy of micrometastatic disease Evans, WJCO 2015

  22. Clinical and Prognostic information How we practically use them (EBM guided)? • Change the type of surgery • Reassure the patient if pCR • Change the adjuvant strategy • Change the duration of treatments • Change the type of radiation • Change the type of controls during the follow-up

  23. If NAST is standard, which standard after NAST? • For HER2+ BC, trastuzumab up to one year can be considered standard (even if pCR?) • What to do if HER2 status changes? (stop or go trastuzumab?) • No established guideline for Chemo in tumors with residual disease at surgery (other chemo? which chemo?) • No established radiotherapy strategy for cN+ becoming ypN0, nor for large tumor obtaining good PR but undergoing to mastectomy. (RT on axilla? RT after mastectomy? • Maybe more questions than answers generated by NAST

  24. Which lessons from the NAST story? • Tumor selection is the first point – we are still imprecise • Patient involvement in the decision is the second point – an honest discussion about the endpoints, the potential true benefits and the limits of NAST must be done • NAST remains the best model to study the activity of new drugs and to evaluate the “in vivo” effects of them, even if it is not automatically the same in other tumor settings.

  25. NAST is NOT the standard, but is one of the possible standards(to be carefully selected for the right situation) NAST in HER2+ & TNBC

More Related